Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Dynasil Biomedical Begins Operation
Apr 2011
WATERTOWN, Mass., April 15, 2011 — Dynasil Corp. of America has announced the incorporation of a new business unit to pursue opportunities in the biomedical field.

Located in Rochester, Minn., Dynasil Biomedical Corp. has hired Dr. Daniel Ericson as its scientific lead with responsibility for research and development. The company purchased for $300,000 Ericson’s rights to six biomedical technologies invented or co-invented by him, as well as certain rights to royalties and milestone payments if the technologies are successfully developed.

Prior to Dynasil Biomedical, Ericson worked at the Mayo Clinic. Several of the assigned technologies are jointly owned with that institution. In addition, he has invented several medical technologies that are in commercial use or are being developed for commercial use by unrelated parties.

One of Ericson’s inventions purchased by Dynasil is a tuberculosis test with the potential to provide a one-hour tuberculosis screening for patients. Present tests require several days, making them unsuitable for Third World countries.

The second invention is for a tissue sealant developed for both topical and internal bleeding. The sealant, which has high tensile strength, accelerates clot formation. The third set of technologies focuses on point-of-care diagnostics for assessing hemophilia, blood coagulation and cardiovascular risk. The tests use finger-stick blood samples and handheld optical detection systems.

All three of the technologies are in the development stage and may require further investment to support development, regulatory approval and commercialization. In this endeavor, the company will collaborate with its RMD Research organization and its RMD Instruments business.

Dynasil expects to make additional investments to accelerate the newly purchased technologies’ release into the market and reports that its investments will be complemented by external research funding.

For more information, visit:  

Americasbiomedical technologiesBiophotonicsblood coagulationBusinesscardiovascular risksDaniel EricsonDynasil Biomedical Corp.Dynasil Corporation of AmericahemophiliaimagingMassachusettsMayo ClinicMinnesotaoptical detection systemspoint-of-care diagnosticsRMD InstrumentsRMD Researchtissue sealanttuberculosis test

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.